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Hepatitis B virus (HBV) is a global virus responsible for a universal disease burden
for millions of people. Various vaccination strategies have been developed using
viral vector, nucleic acid, protein, peptide, and virus-like particles (VLPs) to stimulate
favorable immune responses against HBV. Given the pivotal role of specific immune
responses of hepatitis B surface antigen (HBsAg) and hepatitis B core antigen (HBcAg)
in infection control, we designed a VLP-based vaccine by placing the antibody-binding
fragments of HBsAg in the major immunodominant region (MIR) epitope of HBcAg to
stimulate multilateral immunity. A computational approach was employed to predict
and evaluate the conservation, antigenicity, allergenicity, and immunogenicity of the
construct. Modeling and molecular dynamics (MD) demonstrated the folding stability
of HBcAg as a carrier in inserting Myrcludex and “a” determinant of HBsAg. Regions 1–
50 and 118–150 of HBsAg were considered to have the highest stability to be involved
in the designed vaccine. Molecular docking revealed appropriate interactions between
the B cell epitope of the designed vaccine and the antibodies. Totally, the final construct
was promising for inducing humoral and cellular responses against HBV.
Keywords: hepatitis B virus, epitope, vaccine, virus-like particles, molecular dynamics
INTRODUCTION
There is approximately 257 million people worldwide suffering from hepatitis B infection. Hepatitis
B virus (HBV) causes 887,000 deaths per year due to cirrhosis and hepatocellular carcinoma (HCC)
(1). In spite of the current success in vaccines, hepatitis B disease challenges persist for various
reasons. Firstly, 5–10% of the population remain without vaccine response (non-responders,
<10 IU/L). Further, the dose of the antibody produced in most vaccinated individuals is not fully
Abbreviations: ADCC, antibody-dependent cellular cytotoxicity; APCs, antigen-presenting cells; ARPs BLAST, Basic Local
Alignment Search Tool on allergen representative peptides; CDRs, complementarity determining regions; DARS, Decoys as
the Reference State; DOPE, discrete optimized potential energy; FFT, fast Fourier transform; HBcAg, hepatitis B core antigen;
HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HMM, hidden Markov model;
IEDB, Immune Epitope Database; KCs, Kupffer cells; LINCS, Linear Constraint Solver algorithm; LSECs, liver sinusoidal
endothelial cells; MAST, Motif Alignment and Search Tool; MD, molecular dynamics; MDSCs, myeloid-derived suppressor
cells; MIR, major immunodominant region; MOG, myelin oligodendrocyte glycoprotein; MSA, multiple sequence alignment;
NPT, constant number of particles, pressure, and temperature; NTCP, sodium taurocholate co-transporting polypeptide;
NVT ensemble, constant number of particles, volume, and temperature; PME, particle mesh Ewald; RMSD, root-mean-
square deviation; RMSF, root-mean-square fluctuation; RoG, radius of gyration; RRIDs, Research Resource Identifiers;
SAbDab, Structural Antibody database; SVM, support vector machine; VLP, virus-like particle.
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protective (low responders, <100 IU/L) (2). Another reason is
the emergence and spread of vaccine-induced immune escape
mutants that are resistant to the effects of the existing vaccines
(3). Finally, there is lack of effective treatment for chronic
hepatitis B patients (4). Accordingly, the development of a
new vaccine will be required to enhance seroprotection in
non-responders to current vaccines and to provide therapeutic
immunization for patients with chronic HBV infection.
Hepatitis B virus is an enveloped virion with an icosahedral
nucleocapsid core comprising a partially double-stranded
circular DNA genome. The genome includes four genes that
encode five proteins (5). The envelope proteins [hepatitis B
surface antigen (HBsAg), 388–400 amino acids (aa)] encoded
by the S gene contains three regions of pre-S1 (107–119 aa),
pre-S2 (55 aa), and S (226 aa). Myrcludex (residues 2–48) is
a highly conservative part of the pre-S1 region that triggers
specific binding to the HBV receptor, sodium taurocholate co-
transporting polypeptide (NTCP), in hepatocytes. Further, it
induces antibodies that neutralize immune escape mutants. In
other words, any mutation in this region leads to a missing
virus binding ability to its receptor (6). Myrcludex can also
bypass non- (or low) response to the S region (7). Likewise,
the “a” determinant located at 124–147 amino acids in the S
region of HBsAg is common in all serotypes and genotypes in
HBV (8). Although the “a” determinant is capable of producing
neutralizing antibodies against HBV, the spread of mutations
in P120E, T123N, T126N, Q129L, Q129H, M133L, K141E,
P142S, D144A, G145R, and N146S has diminished its efficiency
(9). The receptor binding potential and the antibody-mediated
neutralization effect of Myrcludex, as well as the high capability
of immunodominant epitopes of the “a” determinant, have spiked
some interest to generate new HBV vaccines.
Hepatitis B core antigen (HBcAg) is a 183- to 185-residue
polypeptide chain from the C gene. Structurally, the HBcAg
monomer is designated as an antiparallel helical protein
connected by a loop that forms the spike feature of capsid. The
spike tip of the virus, the major immunodominant region (MIR;
amino acids 76–82), is known as the insertion site of foreign
epitopes to develop the recombinant HBcAg particles owing to its
role in inducing antigen-specific antibodies (10). The icosahedral
capsid of HBV is composed of the self-assembly HBcAg dimer
proteins that form T = 3 or T = 4 symmetry (11). Interestingly, in
a lack of any homology to human proteins, HBcAg is introduced
as an ideal therapeutic target (12). Further, HBcAg, as a virus-
like particle (VLP), can bypass non- (or low) response to HBsAg
in the current vaccines (13) while also containing CD4+ and
CD8+ T cell epitopes (14). CD8+ T cells have HLA-A2 supertype
epitopes in HBcAg that cover most allele HLA-A (HLA-A∗0201)
in the world’s population (15). Recently, VLP-based vaccines
which include HBcAg as a carrier are remarkable candidates for
the insertion of heterologous fragments in the MIR region (14).
Several therapeutic HBV vaccines hold promise to target
multi-epitopes involved in cellular and humoral immunity.
A promising vaccine candidate with convenient immunological
properties would be achieved by integrating proper fragments
of HBsAg and HBcAg, given their crucial role in priming
neutralizing antibodies and T cells activation, respectively. To
this aim, a construct that contains B cell epitopes (including
the “a” determinant and Myrcludex) for the generation of
neutralizing antibodies and T cell epitopes (HBcAg) for the
stimulation of helper and cytotoxic T cell responses can
overcome the challenges. We implemented a computational
approach to design an HBcAg-based VLP vaccine containing
more immunogenic domains of HBsAg to stimulate broad and
specific B and T cell responses against HBV. Briefly, the full
three-dimensional (3D) structures of HBsAg and HBcAg were
predicted and evaluated due to the lack of an experimentally
determined conformation. Then, the construct containing the
HBcAg dimer as the backbone and inserting fragments of HBsAg
in MIRs was generated and assessed to retain the spike feature of
VLP. Finally, the antigenicity, allergenicity, and immunogenicity
of the ultimate construct were determined in silico.
MATERIALS AND METHODS
Multiple Sequence Alignment and
Phylogenic Studies
To find conserved residues and regions in the large envelope
protein of HBV (HBsAg), multiple sequence alignment (MSA)
was carried out using Clustal Omega [Research Resource
Identifier (RRID): RRID: SCR_001591] at default parameters.
Clustal Omega performs MSA using seeded guide trees and
hidden Markov model (HMM) profile–profile techniques to
generate alignments (16). The reviewed sequences retrieved from
Uniprot were subjected to MSA. The lengths of these sequences
ranged from 328 to 400 aa. Since the D genotype is the most
prominent genotype in Iran and in the Middle East countries (17,
18), MSA was also implemented on the D genotype sequences
(389 aa). The results of both alignments were visualized by Jalview
(RRID: SCR_006459) (19). Moreover, a phylogenetic tree was
built using MEGA7 (RRID: SCR_000667) (20).
Secondary and Tertiary Structure
Prediction and Validation
The secondary structures of the large envelope protein (HBsAg;
isoform L, genotype D, UniProt ID: P03138) and core antigen
(HBcAg; UniProt ID: Q67855) were predicted using PHD and
NetSurfP web servers. PHD (RRID: SCR_018778) is a neural
network system which uses evolutionary information of a protein
to predict an accurate enough 2D structure as the initial point of
3D modeling (21). The sequence-based approach of NetSurfP-2.0
(RRID: SCR_018781) could promote accuracy in predicting the
geometrical features of proteins by integrated deep learning (22).
For tertiary structure prediction, structural alignment for the
primary sequences of HBsAg and HBcAg was performed using
InterPro Scan and HHpred at their default parameters to find
homologous structures. HHpred (RRID: SCR_010276) provided
the query-template alignment using the PDB_mmCIF70 database
(23). The results introduced the crystal structure of HBcAg as
reported by [24]. Although the sequence identity of the template
(PDB ID: 1QGT) with HBcAg was defined to be 94%, the amino
acid coverage of the 3D structure was related to the assembly
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domain of the protein in the N-terminal (residues 1–140). There
was no template for the nanopeptides (residues 141–149) and the
protamine domain in the carboxy terminal (residues 150–183).
Thus, a combination of ab initio and homology modeling was
used for modeling the entire HBcAg proteins.
Likewise, as the appropriate templates for HBsAg were only
found for a few numbers of the residues in the N-terminal, the
ab initio modeling was applied for protein structure prediction.
Even if the online QUARK server (RRID: SCR_018777) allows
a sequence length less than 200 amino acids, according to
the community-wide critical assessment of protein structure
prediction (CASP) experiments, its fragment-based assembly
approach generates high-quality models for proteins with no
homologous templates (25, 26). In this regard, the sequences
of 1–200 of the N- and C-terminals of protein, including
Myrcludex and the “a” determinant regions, were subjected to the
QUARK server using default options to construct the 3D protein
model, separately. Then, homology modeling was performed to
obtain the entire 3D structure of the HBsAg protein. Finally,
the stereochemical and geometrical quality of the modeled 3D
structures was evaluated and validated using several web tools,
including Verify3D, ProSA, and RAMPAGE (27–29).
Vaccine Design Process
The sequences of various lengths of the C- and N-terminal
pre-S1 and S domains of HBsAg (including Myrcludex and
the “a” determinant) were inserted into the MIR (between
residues 78 and 79) of each monomer of the dimer HBcAg
protein. For conformational study of each VLPs-based vaccine,
the 3D structure of the fusion particles was predicted through
comparative homology modeling using the Modeller v9.19
program (RRID: SCR_008395) at default parameters (30). The
predicted 3D structures of the HBsAg and HBcAg proteins
were used as the template. For each fusion protein sequence,
10,000 generated models were ranked based on the discrete
optimized potential energy (DOPE) score. Then, top 10 models
were visualized and analyzed using PyMol software (RRID:
SCR_000305) (31). The structural disorders in four helices of
HBcAg due to the insertions were evaluated by aligning with the
dimer HBcAg protein. A final model, as the designed VLP-based
vaccine, was selected after stereochemical quality validation and
optimization and was subjected to the following analysis.
T Cell Epitope Prediction
The sequence of the designed VLP-based vaccine was conducted
for T cell epitope prediction using the online prediction server
Immune Epitope Database (IEDB; RRID: SCR_006604) (32, 33).
Considering the associations of specific HLA allele variants with
the outcome of HBV infection, three sets of HLA alleles were
subjected to T cell epitope prediction. The first set was the most
common MHC I (HLA-A∗0201)- and MHCII (HLA-DRB1)-
restricted T cells in the general population. The second set
was positive responders to HBV vaccination, including HLA-
DRB1∗0101, HLA-DRB1∗0401, HLA-DRB1∗1301, and HLA-
DRB1∗1501. The third set consisted of MHC I (HLA-B8)-
and MHCII (HLA-DRB1∗0301, HLA-DRB1∗0701, and HLA-
DQB1∗0201)-restricted T cells which were associated with non-
responders to hepatitis B vaccine (34, 35). The default parameters
of the prediction tools were set to predict the MHC-I and MHC-II
epitopes as nanopeptides and 15-mer peptides, respectively.
Prediction of B Cell Epitopes
Linear B cell epitopes of the designed VLP-based vaccine were
predicted using the IEDB database. Certain features of the protein
correlated with continuous antibody epitopes (hydrophilicity,
flexibility, accessibility, turns, exposed surface, polarity, and
antigenicity) were analyzed using Parker hydrophilicity
prediction, Karplus and Schulz flexibility scale, Emini surface
accessibility scale, Chou and Fasman beta turn prediction, and
Bepipred methods, respectively (36–40). Further, the Ellipro
method in the IEDB database was used to identify discontinuous
B cell epitopes based on solvent accessibility and flexibility (41).
Evaluating the Antigenicity and
Allergenicity of the Designed VLP-Based
Vaccine
The allergenicity of the designed VLP-based vaccine was
predicted using the AlgPred (RRID: SCR_018780) and AllerTOP
web servers (RRID: SCR_018496) (42, 43). Estimation in hybrid
approach of AlgPred, which is a combination of support
vector machine (SVM), IgE epitope, blast search on allergen
representative peptides (ARPs BLAST), and Motif Alignment
and Search Tool (MAST), allowed a reliable allergenic assay
of proteins. Likewise, AllerTOP implemented the k-nearest
neighbors (k-NN) as a machine learning method for the
classification of allergens with 85.3% accuracy.
Further, the antigenicity of the designed VLP-based vaccine
was evaluated using the VaxiJen v2.0 (RRID: SCR_018514)
and ANTIGENpro (RRID: SCR_018779) web servers (44,
45). The free online VaxiJen 2.0 server classifies antigens
considering the physicochemical properties of the protein
in an alignment-independent manner. ANTIGENpro predicts
the protein’s antigenicity using a sequence-based method and
machine learning classifier as a trained predictor via protein
microarray analysis. The default parameters of the prediction
tools were set to estimate the antigenicity and allergenicity.
Immune Simulation
Computational immune simulation was performed using the
C-ImmSim server (RRID: SCR_0187751) to characterize the
immune response profile of the designed VLP-based vaccine
(46). This server implements machine learning techniques for
the prediction of immune interactions through simultaneously
simulating three anatomical regions found in mammals: the bone
marrow, the thymus, and the lymph node. In accordance with
the routine administration schedule for the hepatitis B vaccine in
adults, three injections were given at 0, 1, and 6 months (47). The
simulation parameters were set at default with time steps set at 1,
90, and 540 (each time step is 8 hours). The results of the cellular
and humoral response were interpreted from the plots.
1http://150.146.2.1/C-IMMSIM/index.php
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Molecular Dynamics Simulations
To investigate the conformational stability of the designed
VLP-based vaccine under physiological conditions, molecular
dynamics (MD) simulations were performed and compared to
the HBcAg. MD simulations were implemented in GROMACS
5.1.5 (RRID: SCR_014565) using Amber99SB-ILDN force field
(48). The system was prepared with the SPC/E water model
in a cubic solvation box with a distance of 1.0 nm and then
neutralized with Na and Cl ions. The structure was relaxed
by energy minimization using the steepest descent algorithm
with a maximum force constraint of 1,000 kJ mol−1 nm−2.
The long-range electrostatic interactions were calculated with
the particle mesh Ewald (PME) method. The Linear Constraint
Solver (LINCS) algorithm was used to constrain bonds. Prior to
the MD simulation, the temperature of the system was stabilized
under an NVT ensemble (constant number of particles, volume,
and temperature) at 310 K for 100 ps with the Berendsen
thermostat method. Then, the system was equilibrated under
constant number of particles, pressure, and temperature (NPT)
with the pressure coupling of Parrinello–Rahman for 100 ps. MD
simulations were run for a period of 100 ns with 2-fs time steps.
The trajectories of the MD simulations were analyzed for root-
mean-square deviation (RMSD), root-mean-square fluctuation
(RMSF), and radius of gyration (RoG).
Molecular Docking
Experimentally, the X-ray structure is a suitable way to obtain
the conformation of the antibody–antigen complex as well as
atomic interactions on their interface. Nowadays, computational
docking provides a fast and inexpensive route to obtain
reasonable results (49). The molecular interactions between the
designed VLP-based vaccine and the anti-HBsAg antibodies were
studied using the ClusPro web server (RRID: SCR_018248) in
the antibody mode (50). This web server predicts the antibody–
antigen complexes using a combination of Decoys as the
Reference State (DARS) and the docking program PIPER based
on the fast Fourier transform (FFT) correlation approach. The
3D structures of the anti-HBsAg antibodies were obtained from
PDB (PDB IDs: 1H3P, 4Q0X, and 5YAX). The complementarity
determining regions (CDRs) of the antibodies were defined by
the Kabat, Chothia, and IMGT numbering schemes using the
Structural Antibody database (SAbDab) (51). The complexes
were visualized using PyMOL software and analyzed using
Ligplot+ software (RRID: SCR_018249) (52).
RESULTS
HBsAg, Combination of Conserved
Sequence, and Various Evolutionary
Genotypes
Multiple sequence alignment was carried out to find the
conserved regions among the large envelope protein of various
genotypes of HBV (HBsAg). Although the MSA results revealed
higher conservation in the whole sequence of HBsAg among
the genotypes (Supplementary Figure S1), it is reported
that the pre-S1 and S domains of HBsAg represented the
adaptive evolutionary feature which provides heterogeneous
viral genotypes. This hallmark could be interpreted given the
pivotal role of these domains of HBsAg in viral replication and
infection in the host (53). The results have been presented in
a phylogenetic tree with the neighbor-joining (NJ) method in
MEGA7 (Figure 1A). The bootstrap consensus tree concluded
from 1,000 replicates was taken to represent the evolutionary
relation of the analyzed sequences of the large envelope protein
in various genotypes of HBV. The percentage of replicate trees
in which the associated proteins clustered together was assigned
above the branches. The evolutionary distances were computed
using the Poisson correction method. The analysis involved 46
amino acid sequences. The phylogenetic tree showed a close
relationship between HBsAg of genotypes A and B, and then C
and D, while in genotypes E, F, and G, it was more divergent from
the other genotypes. Furthermore, MSA of the HBsAg sequences
among the D genotype, which is illustrated by conservation based
on Blosum62 matrix, showed high conservation in most regions.
However, a few amino acid differences in their sequence led to
sub-genotypes D1–D7 (Figure 1B).
Prediction and Validation of HBsAg and
HBcAg Structures
In parallel with MSA, the secondary structures of HBsAg and
HBcAg were analyzed to determine the structural content of
the amino acid sequence as alpha helix, extended strand, turn,
and coil. The result is depicted in Figure 2 and summarized in
Table 1. The conformational content predicted for the HBcAg
protein was consistent with its crystallographic structure, and
as expected, much of its structure was composed of the alpha
helix. In contrast, the coiled and alpha helix contents in the
HBsAg protein were tantamount, which should be noted when
predicting the third structure. Likewise, the structural feature
of the HBsAg protein, including the surface accessibility as
well as residue disorders and phi–psi dihedral angles of the
amino acids in the sequence, was investigated and depicted in
Supplementary Figure S2.
After evaluating the predicted model by QUARK for the
nanopeptides (residues 141–149) and the protamine domain in
the carboxy terminal (residues 150–183) of HBcAg, homology
modeling was performed using Modeller v9.19 software. A total
of 10,000 generated models were ranked based on the DOPE
score to find the top 10 models for conformational analysis.
Likewise, the 3D model related to the N- and C-terminal domains
of HBsAg was obtained from QUARK. The predicted models
were introduced to Modeller as templates in order to design
the entire HBsAg. The overall quality of the final models of
proteins was rated by Z-score in ProSA, which illustrated the
quality of the predicted models compared to the experimentally
validated structure of the proteins (X-ray and NMR) (Figure 2).
The torsional angles of the protein backbone were analyzed in
the predicted models by the Ramachandran plot. Although there
were 2.2 and 3.6% outlier residues in the predicted models of
HBcAg and HBsAg, respectively, the high amounts of residues
located in the favored and allowed regions confirmed the quality
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FIGURE 1 | The evolutionary relation was derived using the neighbor-joining method and multiple sequence alignment of hepatitis B surface antigen (HBsAg) among
hepatitis B virus (HBV) genotype D. (A) The bootstrap consensus tree concluded from 1,000 replicates was taken to represent the evolutionary relation of the
analyzed sequence of the large envelope protein of various genotypes of HBV. The percentage of replicate trees in which the associated proteins clustered together
was visible above the branches. The evolutionary distances were computed using the Poisson correction method. The analysis involved 47 amino acid sequences.
Evolutionary analyses were conducted in MEGA7. (B) The sequences have been colored by conservation based on the Blosum62 matrix in Jalview. The most
dominant genotype of HBsAg in Iran, genotype D1, is depicted by red dashed lines.
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FIGURE 2 | Hepatitis B surface antigen (HBsAg) and hepatitis B core antigen (HBcAg) representations, the Z-score ProSA plots of the structures, and their cartoonic
representation. (A) Schematic view of the S gene in HBV. (B) Three-dimensional (3D) structure of an HBsAg (residues 1–389). Myrcludex and the “a” determinant
regions are shown in red and blue, respectively. (C) 3D structure of the HBcAg dimer (the MIR in monomers is shown in magenta and yellow). (D–F) Secondary
structure prediction of HBsAg, HBcAg dimer, and the designed virus-like particle (VLP)-based vaccine. The alpha helix, extended strand, and random coils are
indicated in blue, red, and pink lines, respectively. (G–I) ProSA plots of HBsAg, HBcAg, and the VLP-based vaccine. Black spot represents the evaluation of the input
structure within the range of experimentally determined structure for proteins of similar size.
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TABLE 1 | Secondary and tertiary structure validations.
ProSA Z-score RAMPAGE Verify3D score (%) PHD
Favored (%) Allowed (%) Outlier (%) Alpha helix Extended strand Random coil
HBcAg −2.23 89.2 8.6 2.2 82.23 51.08 11.35 37.57
HBsAg −4.76 80.7 15.7 3.6 80.05 39.46 10.9 49.64
VLP-based vaccine −2.26 85.6 11.2 3.2 80.17 45.63 12.78 41.59
of the modeling. As the results of the secondary structure
predictions were compatible with the 3D models, Verify3D scores
also designated the adaptability of the 3D–1D structures. A score
higher than 80% is denoted as the remarkable amount of amino
acids with a score ≥0.2 in the 3D/1D profile (Table 1).
Structural Analysis of the VLP-Based
Vaccine
In order to preserve the self-assembly feature of the α-helical
HBcAg, conformational disorders due to the insertion of
heterolength epitopes in the MIR loops were evaluated precisely.
As shown in Figure 3, generating models by inserting various
lengths of the Myrcludex region (1–50) of HBsAg resulted
in divergent perturbations of the α-helical structure of the
HBcAg protein. The minimum disarrangement was related to the
insertion of the entire sequence of Myrcludex. Similarly, the effect
of different fragments of the “a” determinant region of HBsAg was
determined on the stability of the helical capsomere. Note that
the change of even a single amino acid in the fragment length of
the “a” determinant disrupted the HBcAg capsid helix structure.
The insertion of an extended length of the “a” determinant has
led to the minimum irregularity of the carrier capsid structure.
Finally, specific protein fusion was constructed by inserting
regions 1–50 of Myrcludex in the first monomer and regions 118–
150 of HBsAg in the second monomer of dimer HBcAg. The
stereochemistry and geometry of the final VLP were investigated
following MD simulation analysis of model (Table 1).
T Cell Epitope Identification on the
VLP-Based Vaccine
The final sequence of the designed VLP-based vaccine was
analyzed to look for the sequence of T cell epitopes. The
potent MHC I-restricted cytotoxic T cell epitopes were predicted
using the IEDB recommended 2.18 [artificial neural network
(ANN), stabilized matrix method (SMM), and combinatorial
peptide libraries (CombLib)], NetMHCpan4.0, NetCTLpan, and
MHC-NP servers. The 15-mer MHC II binding epitopes were
collected using the IEDB recommended 2.22 (NN-align, SMM-
align, CombLib, and Sturniolo) and NetMHCIIpan3.2 servers.
The predicted output of each allele set was sorted by percentile
rank to find sequences with higher affinity of binding. The range
of percentile rank ≤1 (IC50 values <50 nM) was reported as
high-affinity peptide sequences, while the percentile rank ≤10
(IC50 values <500 nM) was considered as intermediate affinity
of binding. T cell-predicted epitopes on the full sequence form of
fusion candidates are listed in Table 2.
Prediction of B Cell Epitopes Revealed
the Potency of the Inserted Fragments of
HBsAg
The continuous antibody epitopes on the full length of the
designed VLP-based vaccine were predicted using methods in the
IEDB server. Considering the various physicochemical properties
of the residues in the different mentioned methods, several
linear sequences were delineated as B cell epitopes based on
the scores above the default thresholds (Figure 4). Details
on the location of the assigned epitopes indicated that the
inserted fragments of HBsAg into HBcAg tend to be potent
antibody epitopes. Further, discontinuous antibody epitopes
were estimated using ElliPro based on the 3D structure of
the designed vaccine. Firstly, Ellipro computed the shape of
the protein as an ellipsoid. Then, the protrusion index (PI)
of the residues was calculated as a measure of the atoms
lying inside or outside the ellipsoid. Finally, the neighboring
resides were clustered based on the PI scores. Higher scores
were defined as more extensive solvent accessibility of the
residues. The PI values of chains A and B were 0.724 and
0.672, respectively, which were above the minimum threshold
of the program (default score, 0.5). The 3D view of the
predicted discontinuous B cell epitopes for each monomer is
depicted in Figure 4.
The Antigenicity and Allergenicity of the
Vaccine Candidate Were Predicted
The original sequence of HBcAg and the final sequence of
the designed VLP-based vaccine were conducted to predict
the allergenic property using the AllerTOP v.2 and AlgPred
servers. Allergenicity was predicted based on the amino
acid composition and mapping of the IgE epitope, which
revealed that both sequences were non-allergens. Further, the
antigenic trait of the designed vaccine (HBcAg including
Myrcludex and the “a” determinant sequence of HBsAg) was
estimated by VaxiJen 2.0 server to be 0.5449, with a virus
model at thresholds of 0.4 and 0.498854 with ANTIGENpro.
The scores for the original HBcAg were predicted to be
0.5245 and 0.359569 by the VaxiJen and ANTIGENpro
servers, respectively. The results defined the sequences as
probable antigens.
Immune Simulation
The C-ImmSim model illustrates both the humoral and the
cellular responses of a mammalian immune system to the
presence of antigens at the cellular level. The results of the
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FIGURE 3 | Structural view of the designed virus-like particle (VLP)-based vaccine. (A) Overview of final stable VLP-based vaccine [insertion of 1–50 of the
Myrcludex region of HBsAg in the first monomer of HBcAg (red) and 118–150 of the “a” determinant of HBsAg in the second monomer (blue)]. (B) Structural
alignment of the VLP-based vaccine and the HBcAg dimer in green and cyan, respectively. (C–H) Close-up view of various “a” determinant insertions in the
immunodominant region (MIR) of the second monomer (118–150, 123–150, 121–147, 124–147, 121–148, and 123–148, respectively). (I–N) Close-up view of a
range of Myrcludex insertions in the MIR of first the monomer (1–50, 2–48, 1–21, 9–48, 18–48, and 20–48, respectively).
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TABLE 2 | Predicted MHC class I and II epitopes of the designed virus-like particle (VLP)-based vaccine.
HLA sets in HBV MHC Allele Position Sequence Percentile rank*
Common MHC I HLA-A*02:01 18–27, 253–262 FLPSDFFPSV 0.11
MHC II HLA-DRB1*01:01 163–177, 382–396 ETVLEYLVSFGVWIR 4.4
Non-responder MHC I HLA-B*08:01 214–222, 222–230,
431–444, 441–449
SPRRRRSQS 0.3
207–215, 426–434 SPRRRTPSP 0.2
150–158, 369–377 LLWFHISCL 0.5
142–150, 361–369 NMGLKIRQL 1
MHC II HLA-DRB1*03:01 20–34, 255–269 PSDFFPSVRDLLDTA 7.1
HLA-DRB1*07:01 162–176, 381–395 RETVLEYLVSFGVWI 2.8
144–158, 363–377 GLKIRQLLWFHISCL 7
HLA-DQB1*02:01 11–25, 246–260 ATVELLSFLPSDFFP 0.77
5–19, 240–254 PYKEFGATVELLSFL 0.92
13–27, 248–262 VELLSFLPSDFFPSV 0.94
10–24, 245–259 GATVELLSFLPSDFF 0.97
Positive responsive MHC II HLA-DRB1*13:01 163–177, 382–396 ETVLEYLVSFGVWIR 0.53
169–183, 388–402 LVSFGVWIRTPPAYR 0.53
HLA-DRB1*15:01 163–177, 382–396 ETVLEYLVSFGVWIR 0.84
HLA-DRB1*04:01 132–146, 351–365 RDLVVNYVNTNMGLK 2.5
*Percentile rank ≤1: high-affinity peptide sequences with the antigenic property; percentile rank ≤10: intermediate-affinity peptide sequences with the antigenic property.
immune simulation indicated appropriate responses of cellular
and humoral immunity to the designed VLP-based vaccine. The
cellular immune response was determined by an increase of
T helper 1 cells and no T regulatory response was detected
(Figure 5A). The humoral response was characterized by high
levels of IgM and IgG (IgG1 + IgG2) consequently of three
vaccine injections (Figure 5B).
The Designed VLP-Based Vaccine Was
Hopefully Stable and Folded During MD
Simulations
The conformational behavior of the designed vaccine during
simulations was checked by calculating the backbone RMSD
with respect to the initial structure. Figure 6A presents the
results compared to the dimer-designed vaccine. Despite limited
fluctuations during the simulations, the final structure of
the protein has reached acceptable stability. The compactness
and folding of the protein structure was investigated by the
RoG (Rg). The relatively stable diagram of this parameter
during the simulation indicated the conservation of protein
folding. This value for HBcAg and for the designed vaccine
proteins showed similar ranges, which could be promising
in preserving the 3D structure of the capsomeres after the
addition of HBsAg fragments (Figure 6B). Analysis of the
fluctuation of residues, via RMSF, indicated the residue’s
movements during the simulation. The utmost of the amino
acid displacements related to their initial positions were
at the two ends of the proteins. However, some of the
oscillations were associated with the regions where fragments of
HBsAg were added to the capsomeres. The overall fluctuations
in the two proteins were balanced and within the same
range (Figures 6C,D).
Molecular Docking
ClusPro docking server is recommended to provide a file
consisting of non-CDRs of the antibody. The heavy and light
chains of the 1H3P, 4Q0X, and 5YAX antibodies were analyzed
in the SAbDab server using various numbering schemes (Kabat,
Chothia, and IMGT) to determine CDR residues. Since these
antibodies were anti-Myrcludex region of HBsAg, the molecular
interactions of HBc VLPs were investigated focusing on the
first monomer. However, there was no released 3D structure
of the anti-“a” determinant region of the HBsAg antibody.
The analysis revealed that the major residues of CDRs of the
H and L chains were located in the loops of antibodies and
cooperatively interacted with Myrcludex residues of the VLP-
based vaccine. Details of these interactions in terms of the
interacted residues and hydrogen bonds have been drawn up
by Ligplot+ (Supplementary Figures S3–S5) and visualized by
PyMol (Figure 7).
The bioinformatics tools that were used in the study and
their descriptions are summarized in Table 3. The RRIDs were
extracted from the Resource Identification Portal.
DISCUSSION
In recent years, several therapeutic vaccination approaches
have been developed for HBV to boost the immune system
and ideally eradicate the virus. VLP-based vaccines include
HBcAg as a carrier, a known candidate for the insertion of
heterologous fragments in its MIR region (14). The aim of this
study was to design an HBcAg-based VLP vaccine containing
more immunogenic domains of HBsAg to induce multivalent
immune responses.
We initially investigated the sequence conservation of HBsAg
within known HBV types despite phylogenetic variations that led
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FIGURE 4 | Predicted B cell epitopes of the designed virus-like particle (VLP)-based vaccine. (A) Linear B cell epitopes based on the various physicochemical
properties of the residues. The red boxes are related to the first and second fragments of hepatitis B surface antigen (HBsAg) inserted into hepatitis B core antigen
(HBcAg). (B) Predicted discontinuous B cell epitopes for each monomer of the designed vaccine.
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FIGURE 5 | C-ImmSim representation of the immune stimulation of the designed virus-like particle (VLP)-based vaccine. (A) Phenotypic evaluation of T helper cells
against a vaccine injection. (B) Generation of immunoglobulins in response to vaccine injections (0, 1, and 6 months). Specific subclasses are demonstrated as
colored peaks.
us to select two regions with an overall conserved sequence in the
C- and N-terminals of protein. There are many plausible merits
to explain the choice of these regions for incorporation into the
final structure as a promising designed vaccine.
The main advantage of selecting these specific regions
(“a” determinant and Myrcludex) of HBsAg rather than its
entire structure in the vaccine construct is based on the roles
of HBsAg in immunosuppression mechanisms in hepatitis B
disease. HBsAg can inhibit innate immunity by blocking Toll-
like receptor signaling pathways in Kupffer cells (KCs) and liver
sinusoidal endothelial cells (LSECs) (54, 55). Also, HBsAg can
defect dendritic cells, which are known as the most important
antigen-presenting cells (APCs) (56). HBsAg may impair CD8+
T cell responses through persistent antigen stimulation (57–59).
It can repress T cell responses by stimulating the differentiation
of monocytes into myeloid-derived suppressor cells (MDSCs)
and boost the regulatory T cell response (60, 61). In this regard,
the cellular immune profile of the designed VLP-based vaccine
comprising the specific regions of HBsAg indicated an increase
of T helper 1 cells and no T regulatory response.
Additionally, studies have shown a link between multiple
sclerosis and the existing HBV vaccine, with the mechanism
relying on the amino acid similarity between HBsAg and the
myelin oligodendrocyte glycoprotein (MOG) or other myelin
antigens (62). Further, HBsAg-specific CD8+ T cells may be an
essential trigger to induce HBV-associated HCC (63).
Another advantage of this construct over the current vaccines
was the coverage of escaped mutants. This feature was derived
from the Myrcludex fragment where any mutation in this region
reduces the pathogenesis of the virus (64). Also, antibodies
produced against this construct can eliminate virus-infected
cells using the antibody-dependent cellular cytotoxicity (ADCC)
mechanism. The presence of HBcAg in this construct compared
to the current vaccine allows the production of CD8+ T cell
responses and, subsequently, the eradication of reservoirs of
chronic HBV (65).
Exhausted T cells that are present in the chronic type of
hepatitis B disease have been characterized as follows: decreased
cytokine production, increased expression of inhibitory receptors
such as PD1 and CTLA-4, etc. (66). It has been shown that core-
specific CD8+ T cells have a less defected functionality than other
specific CD8+ T cells due to their mildly exhausted phenotype.
Thus, this finding demonstrates that core-specific CD8+ T cells
can represent promoted responsiveness to PD1 pathway blockade
(67, 68).
The CD4+ T cell epitopes on our vaccine construct enabled
the induction of cytokines and signals required to strongly
stimulate the adaptive immune response. Indeed, molecular
analysis of HLA class II exhibited that high-affinity ligands for
the diversity of class II alleles were more common for HBcAg
than for the envelope antigens, particularly HBsAg. Studies
have found that HBcAg is about 100-fold more immunogenic
than HBsAg at both the T helper cell and B cell levels
(35). Finally, allergenicity analysis of the designed vaccine
indicated that it was neither an allergen nor it may cause any
hypersensitivity reactions.
The designed vaccine relied on the self-assembling feature
of HBcAg, which preserved VLP formation. Considering the
importance of proper folding in the antiparallel helices of HBcAg
forming the spikes, a vast range of insertion sequences of HBsAg
have been evaluated to allow the least structural movement of the
carrier. Finally, fragments of 1–50 at the N-terminal (Myrcludex)
and 118–150 at the C-terminal (“a” determinant) passed the
evaluations to preserve the backbone folding of HBcAg.
Regarding estimation of the cellular and humoral immunity
due to the designed vaccine, T cell prediction as well as B cell
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FIGURE 6 | Molecular dynamics (MD) analysis of hepatitis B core antigen (HBcAg) and the designed virus-like particle (VLP)-based vaccine during 100-ns
simulations. (A) Root-mean-square deviation (RMSD) plot of proteins indicating acceptable stability of the structures. (B) Radius of gyration (RoG) plot of proteins
representing stable folding of the structures. (C,D) Root-mean-square fluctuation (RMSF) plots of HBcAg and the designed vaccine, respectively. The red boxes
indicate the region of inserted fragments into HBcAg.
identification showed acceptable results of the efficacy of the
construct. Some HLA alleles have a positive influence on the
immune response to hepatitis B vaccine, such as DRB1∗1301,
DRB1∗1501, and DRB1∗0401. The results indicated that the
designed vaccine can be identified by these alleles. The positive
responsiveness of HLA class II elicits antibody production by
activating T helper cells and subsequently stimulating B cells.
Further, the presence of weak antibody responses to the common
hepatitis B vaccine is attributed to HLA non-responders, such
as HLA-B∗0801, DRB1∗0301, DRB1∗0701, and DQB1∗0201.
The designed vaccine contained epitopes for these alleles and
could bypass their effects. Consistent with the B cell stimulating
potential of the designed VLP-based vaccine, the humoral
response in the results of the immune simulation was specified
by the high levels of IgM and IgG (IgG1 + IgG2) consequently of
three vaccine injections.
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FIGURE 7 | Binding model of the designed virus-like particle (VLP)-based
vaccine and antibodies. (A) 1H3P-designed vaccine complex.
(B) 4Q0X-designed vaccine complex. (C) 5YAX-designed vaccine complex.
The heavy and light chains of antibodies are colored in green and slate blue,
respectively. The complementarity determining regions (CDRs) of the H and L
chains are displayed in magenta and yellow, respectively. The designed
vaccine, Myrcludex, and the “a” determinant are reflected in cyan, red, and
dark blue, respectively.
In addition, the presence of epitopes identified by HLA
class I enables the construct to eliminate hepatitis B-infected
cells through the induction of cytotoxic T cells (CD8+
T cells) and related mechanisms such as IFN-γ, perforin,
and granzyme, so it can cover chronic hepatitis B patients
(therapeutic effect).
B cell epitope prediction revealed that the inserted HBsAg
fragments represented their promising functionality to induce
an anti-HB antibody response. These regions were detected as
linear B cell epitopes in the construct. Also, to evaluate this
feature, interactions of the designed vaccine with anti-HBsAg
were studied by molecular docking. The analysis indicated that
the designed vaccine specifically interacted with anti-Myrcludex
in their CDRs, suggesting that B cell epitope related to HBsAg–
Myrcludex was recognized by the antibodies. However, there
TABLE 3 | Bioinformatics tools in the study.
Tools Description RRID
Clustal omega Multiple sequence
alignment (MSA)
SCR_001591
MEGA7 Phylogenetic tree SCR_000667
PHD web server Secondary structure
prediction
SCR_018778

















T cell, B cell epitope
prediction
SCR_006604
AlgPred web server Allergenicity prediction SCR_018780
AllerTOP web server Allergenicity prediction SCR_018496
VaxiJen Antigenicity prediction SCR_018514)
ANTIGENpro Antigenicity prediction SCR_018779




ClusPro web server Molecular docking SCR_018248





was no released anti-“a” determinant 3D structure to assess the
second insertion.
An ideal vaccine needs to be inducible for both neutralizing
antibodies and cellular immunity. Along with the immunogenic
role of HBsAg, HBcAg is reported to be well suited in priming
B cells via the activation of T cells. A combination of HBsAg-
and HBcAg-based vaccines has been evaluated in research of
finding proper strategies for chronic hepatitis B patients. Their
incorporation can form a highly immunogenic structure to
enhance humoral immunity against both antigens (69). In our
study, in silico assessments of the designed vaccine showed
the feasibility of humoral and cellular immunogenicity while
declaring no allergenicity effect. Taken together, the synergistic
effect of HBsAg and HBcAg could be an appealing approach to
developing a wider-spectrum vaccine against HBV in acute as
well as in chronic cases.
CONCLUSION
This study evaluated a computational strategy to develop a
VLP-based vaccine against HBV by inserting HBsAg fragments
into the MIR region of HBcAg. Although T cell/B cell epitope
predictions as well as the immune response profile of the designed
vaccine displayed defensible features in feasibly stimulating
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humoral and cellular immunity, we recommend in vitro/in vivo
studies to determine therapeutic efficacy for the treatment
of HBV infection.
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